ELISA/assay

Human histidine-rich glycoprotein, HRG ELISA Kit

MBS702853

96 Strip Wells

760 USD

ELISA Kit

Human histidine-rich glycoprotein, HRG ELISA Kit

histidine-rich glycoprotein

Human histidine-rich glycoprotein (HRG) ELISA kit; DKFZp779H1622; HPRG; HRGP; histidine-proline rich glycoprotein; histidine-rich glycoprotein

histidine-rich glycoprotein; Histidine-rich glycoprotein; histidine-rich glycoprotein; histidine-proline-rich glycoprotein; histidine-rich glycoprotein; Histidine-proline-rich glycoprotein; HPRG

HRG

HRG; HRG; HPRG; HRGP; THPH11; HPRG

HRG_HUMAN

Human

525

This assay has high sensitivity and excellent specificity for detection of Human HRG. No significant cross-reactivity or interference between Human HRG and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV% is less than 8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV% is less than 10%. Three samples of known concentration were tested in twenty assays to assess. Sample Type: serum, plasma, tissue homogenates. Detection Range: 6.25 ug/ml-400 ug/ml. Detection Wavelength: 450 nm. Sensitivity: 1.56 ug/ml

Sample Volume: 50-100ul. Protein Biological Process 1: Blood Coagulation. Protein Biological Process 3: Blood coagulation

Introduction: HRG (histidine-rich glycoprotein) contains two cystatin-like domains and is located in plasma and platelets. The physiological function is not yet known. It binds heme, dyes and divalent metal ions. It can inhibit rosette formation and interacts with heparin, thrombospondin, and the lysine-binding site of plasminogen. A potential prothrombotic effect of HRG is indicated by the inhibition of fibrinolysis and the reduction of inhibition of coagulation. Mutations in HRG lead to thrombophilia due to abnormal histidine-rich glycoprotein levels. Principle of the Assay: The microtiter plate provided in this kit has been pre-coated with an antibody specific to HRG. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody preparation specific for HRG and Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then a TMB (3,3',5,5' tetramethyl-benzidine) substrate solution is added to each well. Only those wells that contain HRG, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm +/- 2 nm. The concentration of HRG in the samples is then determined by comparing the O.D. of the samples to the standard curve.

4504489

NP_000403.1

NM_000412.3

P04196

59,578 Da

Dissolution Of Fibrin Clot Pathway 106061!!Hemostasis Pathway 106028!!Platelet Activation, Signaling And Aggregation Pathway 106034!!Platelet Degranulation Pathway 106050!!Response To Elevated Platelet Cytosolic Ca2+ Pathway 106048

This histidine-rich glycoprotein contains two cystatin-like domains and is located in plasma and platelets. The physiological function has not been determined but it is known that the protein binds heme, dyes and divalent metal ions. It can inhibit rosette formation and interacts with heparin, thrombospondin and plasminogen. Two of the protein's effects, the inhibition of fibrinolysis and the reduction of inhibition of coagulation, indicate a potential prothrombotic effect. Mutations in this gene lead to thrombophilia due to abnormal histidine-rich glycoprotein levels. [provided by RefSeq, Jul 2008]

Function: Plasma glycoprotein that binds a number of ligands such as heme, heparin, heparan sulfate, thrombospondin, plasminogen, and divalent metal ions. Binds heparin and heparin/glycosaminoglycans in a zinc-dependent manner. Binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Binds to N-sulfated polysaccharide chains on the surface of liver endothelial cells. Inhibits rosette formation. Acts as an adapter protein and is implicated in regulating many processes such as immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis. Mediates clearance of necrotic cells through enhancing the phagocytosis of necrotic cells in a heparan sulfate-dependent pathway. This process can be regulated by the presence of certain HRG ligands such as heparin and zinc ions. Binds to IgG subclasses of immunoglobins containing kappa and lambda light chains with different affinities regulating their clearance and inhibiting the formation of insoluble immune complexes. Tethers plasminogen to the cell surface. Binds T-cells and alters the cell morphology. Modulates angiogenesis by blocking the CD6-mediated antiangiongenic effect of thrombospondins, THBS1 and THBS2. Acts as a regulator of the vascular endothelial growth factor (VEGF) signaling pathway; inhibits endothelial cell motility by reducing VEGF-induced complex formation between PXN/paxillin and ILK/integrin-linked protein kinase and by promoting inhibition of VEGF-induced tyrosine phosphorylation of focal adhesion kinases and alpha-actinins in endothelial cells. Also plays a role in the regulation of tumor angiogenesis and tumor immune surveillance. Normalizes tumor vessels and promotes antitumor immunity by polarizing tumor-associated macrophages, leading to decreased tumor growth and metastasis.14 PublicationsManual assertion based on experiment in:Ref.9. Cofactor: Zinc.1 PublicationManual assertion based on experiment in:Ref.17

96 Strip Wells

760 USD